Hantavirus, SSRI Controversy, and FDA News | Top 5 in Five

In this episode of Top 5 in Five, Luke Halpern highlights the top 5 pieces of content on the Pharmacy Times website for the week of May 12. Key insights include updates on the ongoing hantavirus situation, a pair of controversial FDA news pieces, and new efforts from Health and Human Services leadership to curb the use of selective serotonin reuptake inhibitors (SSRIs). You can find more expert insights at PharmacyTimes.com, where we provide pharmacy news, clinical insights, & continuing education to help pharmacists deliver drug expertise & accessible patient care. #5 - Everything You Need to Know About Hantavirus: https://bit.ly/3R2AxcF #4 - FDA Blocks Publication of COVID-19 and Shingles Vaccine Safety Studies: What Pharmacists Need to Know: https://bit.ly/494Fl7v #3 - Announcing New Initiatives, RFK Jr Continues Push for Americans to Discontinue Antidepressants: https://bit.ly/49QQfhf #2 - Is Hantavirus Human-To-Human Transmissible?: https://bit.ly/4nyK0EA #1 - FDA Moves to Permanently Close the Door on Compounded GLP-1s: https://bit.ly/4nxht23 Visit Pharmacy Times: https://www.pharmacytimes.com/ Follow Pharmacy Times on social media! X: @Pharmacy_Times Facebook: Pharmacy Times LinkedIn: Pharmacy Times BlueSky: @PharmacyTimes.bsky.social TikTok: @pharmacytimes #pharmacy #politics #pharma #pharmacist #hantavirus #cruise #FDA #HHS #rfkjr #covid #shingles #ssri